United States Constipation Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Chloride Channel Activators, GC-C Agonists, Peripherally Acting Mu-Opioid Receptor Antagonists, Laxatives, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and US Constipation Therapeutics Market Insights, Industry Trend, Forecasts to 2035

USA Constipation Therapeutics Market Insights Forecasts to 2035

• The US Constipation Therapeutics Market Size was Estimated at USD 8.34 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.44% from 2025 to 2035
• The USA Constipation Therapeutics Market Size is Expected to reach USD 13.45 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The US Constipation Therapeutics Market Size is anticipated to reach USD 2.587 Billion by 2035, Growing at a CAGR of 4.44% from 2025 to 2035. The market size growth is attributed to the growing proportion of the geriatric population, sedentary lifestyles, and upsurge in the consumption of analgesic medications.

Market Overview

The United States Constipation Therapeutics Market Size involves the development, production, and distribution of medications that treat constipation. The widespread gastrointestinal condition known as constipation affects people of all ages, genders, ethnicities, and socioeconomic backgrounds. It affects a person's quality of life and, if untreated, can result in health issues. It is characterized by difficult and infrequent bowel movements. Until anorectal issues occur, it is frequently overlooked, despite being one of the most prevalent gastrointestinal complaints in the United States. 3% to 5% of pediatric visits in the US are related to functional constipation, a common subtype that is prevalent in childhood.  Constipation happens when stool persists in the colon for an extended period of time, absorbing too much water and becoming dry and hard. Common causes include drugs, lifestyle modifications, low-fiber foods, inactivity, and disregard for bowel movements. The constipation is treated by several agents such as laxatives, stool softeners or wetting agents, and chloride channel activators. The marketed products of the constipation therapeutics are Dulcoflex, Dulcolax, Maf-Oxide, etc.

The increasing prevalence of constipation in the United States escalates the need for constipation therapeutics, which leads to market growth. For instance, as per the brief literature review it was found that constipation is more prevalent condition in the United States due to poor diet and lack of physical activity, chronic idiopathic constipation (CIC) is a common condition affecting 9%-20% of adults in the US, characterized by unsatisfactory defecation and difficult or infrequent stools.

Report Coverage

This research report categorizes the market size for the US constipation therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the US constipation therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US constipation therapeutics market.

Driving Factors                                                               

The market for constipation therapeutics is fueled by several risk factors, including pelvic floor dysfunction, poor fluid and fiber consumption, decreased colon motility, and poor lifestyle choices. Furthermore, the growing number of cases of enteric nervous system changes or visceral sensory abnormalities that reduce rectal sensation and the urge to defecate is driving market expansion. Constipation therapeutics market growth is additionally being driven by the increasing prevalence of gastrointestinal illnesses, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). These ailments frequently coexist with constipation, underscoring the necessity of targeted and efficient therapies. Due to the increasing awareness of these disorders and the demand for efficient treatments, the market is anticipated to continue growing.

Restraining Factors

The United States constipation therapeutics market faces obstacles such as a stringent regulatory framework, repeated use of the constipation drugs tends to cause side effects such as bloating and gas, and limited awareness may hinder the growth of the market.

Market Segmentation

The USA constipation therapeutics market share is classified into product and end-user.

• The peripherally acting mu-opioid receptor antagonists segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period.

The US constipation therapeutics market is segmented by drug class into chloride channel activators, GC-c agonists, peripherally acting mu-opioid receptor antagonists, laxatives, and others. Among these, the peripherally acting mu-opioid receptor antagonists segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the treatment of opioid-induced constipation and does not affect the analgesic effect of the opioid.

• The hospital pharmacies segment accounted for a substantial share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The US constipation therapeutics market is segmented by distribution channel into retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for a substantial share in 2024 and is expected to grow at a significant CAGR during the forecast period. The sector growth is owing to the rising number of patient visits in IPD and OPD services, the provision of compounding and dispensing medications, and personalized medications.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US constipation therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Allergan
• Takeda Pharmaceuticals
• Pfizer
• Amgen
• AbbVie
• Eisai Inc.
• Johnson & Johnson
• Teva Pharmaceutical
• Mentholatum Company
• Others

Recent Developments:

• In March 2025, Glenmark Pharmaceuticals launched 'Polyethylene Glycol 3350 Powder for Solution' as an OTC product in the US market, a generic equivalent of Bayer HealthCare LLC's MiraLAX Powder for Solution, which prevents and treats occasional constipation.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the US constipation therapeutics market based on the below-mentioned segments:

US Constipation Therapeutics Market, By Drug Class

• Chloride Channel Activators
• GC-C Agonists
• Peripherally Acting Mu-Opioid Receptor Antagonists
• Laxatives
• Others

US Constipation Therapeutics Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies